RNS Number : 8580J
Omega Diagnostics Group PLC
24 December 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Mologic CE Mark Rapid Antigen Test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, welcomes the news that Mologic Ltd ("Mologic") has received CE Mark for it's professional-use COVID-19 Rapid Antigen Test.
In June this year, the Company signed a material transfer agreement ("MTA") with Mologic providing access to raw materials and know-how to manufacture their lateral flow antigen test. The test will provide health professionals an accurate detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs.
As announced at the Interim results in November 2020, Omega has now established its technology transfer team and look forward to updating shareholders in the New Year on how the technology transfer and CE Mark is going, so the Company can sell the Rapid Test under Omega's
VISITECT ® brand.
Colin King, CEO of Omega Diagnostics, said:
"We welcome the news that Mologic has received CE Mark for its Rapid Antigen Test, and are excited about completing the technology transfer and CE Marking in the New Year."
Contacts:
|
Omega Diagnostics Group PLC
|
Tel: 01259 763 030
|
|
Bill Rhodes, Interim Non-Executive Chairman
Colin King, Chief Executive
|
www.omegadiagnostics.com
|
|
Kieron Harbinson, Group Finance Director
|
|
|
|
|
|
finnCap Ltd
|
Tel: 020 7220 0500
|
|
Geoff Nash/Edward Whiley (Corporate Finance)
|
|
|
Alice Lane (ECM)
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: 020 7933 8780 or
[email protected]
|
|
Paul McManus
|
Mob: 07980 541 893
|
|
Lianne Cawthorne
|
Mob: 07584 391 303
|
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
NRAFLFSLFALSFII